aarogya.com
  • Home
  • Complementary Medicine
    • Ayurveda
    • Homeopathy
    • Naturopathy
    • Acupressure
    • Acupuncture
    • Aromatherapy
    • Batch Flower Remedies
    • Home Remedies
    • Massage
    • Yoga
    • Meditation
    • Reiki
    • Bodywork
    • Medical Palmistry
  • Conditions & Diseases
    • Acute Diarrheal Disease
    • Appendicitis
    • Blindness
    • Brucellosis
    • Chicken Pox
    • Conjunctivitis
    • Dysentery
    • Hookworm
    • Japanese Encephalitis
    • Lymphatic Filariasis
    • Plague
    • Rubella
    • Typhoid Fever
    • Yellow Fever
    • Allergy
    • Arthritis
    • Blood Pressure
    • Computer Health Hazards
    • Chikungunya Fever
    • Dengue
    • Guinea Worm
    • Influenza
    • Leprosy
    • Malaria
    • Poliomyelitis
    • Tetanus
    • Whooping Cough
    • Viral Hepatitis
    • Amebiasis
    • Asthma
    • Bronchitis
    • Diagnostic Tests
    • Cholera
    • Diphtheria
    • Hepatitis
    • Irritable Bowel Syndrome
    • Leptospirosis
    • Measles
    • Rabies
    • Tuberculosis
    • Yaws
  • Family Health
    • Children's Health
    • Diet & Nutrition
    • First Aid
    • Fitness
    • Humor & Trivia
    • Men's Health
    • Preventive Health
    • Senior's Health
    • Senior Citizen Corner
    • Teen’s Health
    • Vets and Pets
    • Women’s Health
  • Health Resources
    • Blood Donation
    • Career Opportunities
    • Daily Health Tips
    • Health Programs
    • Featured Hospitals
    • Medical Education
    • Health Professional's Negligence
    • Medical Tourism
    • Video Eye
    • Rural Health
    • Patients' Rights Forum
  • Insurance
    • Euthanasia
    • Health Insurance
    • Health Insurance Policies
    • Insurance Companies
    • Medical Ethics
    • Medical Jurisprudence
    • Research
    • Telemedicine
    • Compare Health Insurance
  • Sex & Sexuality
    • What is Sex & Sexuality?
    • FAQs
    • Marriage & Pregnancy
    • Sex Education
  • Support Groups
    • Addiction
    • Aids
    • Cancer
    • Epilepsy
    • Swine Flu
    • Blood Search
    • Vivah
    • Health Directory
    • Alzheimer's Disease
    • Medical Support Groups
    • Cardiology
    • Depression
    • Depression Screening Test
    • Diabetes
    • Disability
    • Kidney
    • Obesity
    • Pregnancy
    • Schizophrenia
    • Vitiligo
Aarogya.com
Marathi | Gujarati | Register | Login
  • Home
  • News and Updates
  • Year 2013
  • SC Rules For Cheap Cancer Drug

SC Rules For Cheap Cancer Drug

  • Print
Details
Hits: 5707
The Times of India
02 April 2013
New Delhi, India

Novartis Loses Battle To Block Indian Generics

The Supreme Court on Monday rejected pharma giant Novartis AG’s plea to preserve its patent over a life-saving cancer drug, Glivec, drawing a huge sigh of relief from thousands of patients in India and in dozens of developing countries as the fear of an almost 15-fold escalation of drug costs receded. It is the biggest setback for multinational pharma companies, which have been denied patent protection for a series of life-saving drugs in recent years.

Invented in 1991, Glivec is a miracle cure for a type of blood cancer called chronic myeloid leukemia (CML). In this form of cancer, certain bone marrow cells go rogue and produce excessive white blood cells, causing mild fatigue and hip pain initially, but slipping into an out-of-control crisis of zooming platelet and white cell counts. It used to be fatal, but with Glivec, the survival rate is over 95%. Imanitib, the active component, is on the National Essential Drugs List in India.

Aarogya news

Novartis, which reported net profit of $9.6 billion in 2012 on sales of $57 billion, criticised the verdict.

MNCs blast verdict, say it will hurt innovation

T he SC’s decision has come as a big blow to MNCs’ ability to sell lucrative medicines in the country. The main beneficiaries of the ruling will be companies like Cipla, Natco Pharma and Sun Pharma which already market generic Glivec at a fraction of the cost of Novartis product. The ruling cements the role of domestic companies as major suppliers of inexpensive generics not only to its Rs 70,000-crore domestic market, but also across the developing world, and further establishes India as a “the pharmacy of the world”. “This (Supreme Court) ruling is a setback for patients that will hinder medical progress for diseases without effective treatment options,” Novartis India vice chairman and managing director-Ranjit Shahani said on Monday.

When the drug was first commercially sold in 2001, India was moving over from the old patent regime to a new one after signing the international trade and patent related agreements in 1995.

The new patent law came into force in 2005. Novartis could not get a patent on Glivec as it dated from an earlier time when a different patent law prevailed. It tried but the patent tribunal rejected the claim in 2006.

After going through various appeals, Novartis ended up in the apex court pleading that a crucial section 3 (d) of the new patent law was not applicable to Glivec. This section says that just discovering a new form of a substance is not enough to grant a patent, if it does not enhance its “known efficacy”.

Novartis was arguing that a new “beta crystalline” form of Glivec is more effective and hence qualifies as a new invention, and hence should get patent protection.

The Supreme Court, in a 112-page analysis of all the claims and counter- arguments disagreed. It said that the beta crystalline form was nothing new. It has always existed in the original amorphous form.

The landmark judgement means that Indian companies like Natco and Cipla can continue making and selling Glivec, not only for India but to most third world countries.

Cancer

Monday’s Supreme Court judgment dims hopes for some other pharma giants fighting legal battles on patents. Pfizer's cancer drug Sutent and Roche's hepatitis C treatment Pegasys and Merck & Co's asthma treatment aerosol suspension formulation lost their patented status in India last year, decisions the companies are fighting to have reversed.

Many pharma giants are concentrating their legal fire-power on India because it is an $11 billion a year market growing at 13-14 percent annually. Equally important is that India has emerged as the ‘pharmacy of the world” selling over $26 billion worth of cheap generic (non-patent) drugs to most of the poor and still developing countries.

It is estimated that about 80% of the HIV/AIDS patients in the developing world are surviving because of cheap Indian drugs.

Disclaimer: The news story on this page is the copyright of the cited publication. This has been reproduced here for visitors to review, comment on and discuss. This is in keeping with the principle of ’Fair dealing’ or ’Fair use’. Visitors may click on the publication name, in the news story, to visit the original article as it appears on the publication’s website.

0
Introducing Digital Practice for Doctors & Healthcare professionals
Swine Flu
National Award for Outstanding achievement by a Non-Professional - Tushar Sampat
Health Professional's Negligence
Health Professional's Negligence
Records of published articles in the newspapers helps common people about precautions to be taken while seeking the services from health professionals and also helps health professionals to rectify the negligence.
read more…
Specialties
Common Symptoms


Aarogya Network

aarogya.com aims to be India’s leading comprehensive health information portal. The site has sections, which cover almost all the medical specialties and give useful information on various diseases. To enhance its reach, the content is available in Indian languages too. We were the first health website to introduce online support groups. Addiction support and Epilepsy support are examples of some very active and vibrant communities.

» Click here to see all our support groups

Subscribe to Our Newsletter

 Get health related new information.

Pune Aarogya
Digital Media Dedicated to Healthcare of Punekars

Health Tools

  • Health Directory
  • Message Board
  • Health Calculators
  • Depression Screening Test

About Aarogya.com

aarogya.com aims to be India’s leading comprehensive health information portal. The site has sections, which cover almost all the medical specialties

Read more...

Suggestions

This is YOUR site, so if you have suggestions or feedback on how we can improve it for you, please let us know! We do our best to keep up!

Read more...

User Comments

“My name is Paulette Conners and I just had to send you an email thanking you since one of the pages on your site was very helpful!”

  • About Us
  • Company Profile
  • Contact Us
  • Privacy Policy
  • Feedback
  • Disclaimer
  • Sitemap
  • Invite Your Friends

© 2017 www.aarogya.com. All Rights Reserved.